Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/183766
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVilaplana Carnerero, Carles-
dc.contributor.authorAznar Lou, Ignacio-
dc.contributor.authorPeñarrubia María, María Teresa-
dc.contributor.authorSerrano Blanco, Antoni-
dc.contributor.authorFernández-Vergel, Rita-
dc.contributor.authorPetitbò-Antúnez, Dolors-
dc.contributor.authorGil Girbau, Mª Montserrat-
dc.contributor.authorMarch Pujol, Marian-
dc.contributor.authorMendive, Juan Manuel-
dc.contributor.authorSánchez-Viñas, Alba-
dc.contributor.authorCarbonell-Duacastella, Cristina-
dc.contributor.authorRubio Valera, Maria-
dc.date.accessioned2022-03-04T12:45:19Z-
dc.date.available2022-03-04T12:45:19Z-
dc.date.issued2020-05-12-
dc.identifier.issn1661-7827-
dc.identifier.urihttp://hdl.handle.net/2445/183766-
dc.description.abstract: Background: Adherence problems have negative effects on health, but there is little information on the magnitude of non-initiation and single dispensing. Objective: The aim of this study was to estimate the prevalence of non-initiation and single dispensation and identify associated predictive factors for the main treatments prescribed in Primary Care (PC) for cardiovascular disease (CVD) and diabetes. Methods: Cohort study with real-world data. Patients who received a first prescription (2013-2014) for insulins, platelet aggregation inhibitors, angiotensin-converting enzyme inhibitors (ACEI) or statins in Catalan PC were included. The prevalence of non-initiation and single dispensation was calculated. Factors that explained these behaviours were explored. Results: At three months, between 5.7% (ACEI) and 9.1% (antiplatelets) of patients did not initiate their treatment and between 10.6% (statins) and 18.4% (ACEI) filled a single prescription. Body mass index, previous CVD, place of origin and having a substitute prescriber, among others, influenced the risk of non-initiation and single dispensation. Conclusions: The prevalence of non-initiation and single dispensation of CVD medications and insulin prescribed in PC in is high. Patient and health-system factors, such as place of origin and type of prescriber, should be taken into consideration when prescribing new medications for CVD and diabetes.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijerph17103358-
dc.relation.ispartofInternational Journal of Environmental Research and Public Health, 2020, vol. 17, num. 10, p. 3358-
dc.relation.urihttps://doi.org/10.3390/ijerph17103358-
dc.rightscc-by (c) Vilaplana Carnerero, Carles et al., 2020-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationMalalties cardiovasculars-
dc.subject.classificationInsulina-
dc.subject.otherCardiovascular diseases-
dc.subject.otherInsulin-
dc.titleInitiation and Single Dispensing in Cardiovascular and Insulin Medications: Prevalence and Explanatory Factors-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec715708-
dc.date.updated2022-03-04T12:45:19Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
715708.pdf810.21 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons